A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy (NCT06866964)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Who can join: Review the eligibility criteria below.
Location: Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Charlotte, North Carolina
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
- Aurora St. Luke's Medical Center MOB — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (980) 515-5300
Email: margarita.dzhanumova@advocatehealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Germ Cell Tumor
- Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors — Boston, Massachusetts
- Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors — Basking Ridge, New Jersey
- A Study of miRNA 371 in Patients With Germ Cell Tumors — Gilbert, Arizona
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors — Birmingham, Alabama
- A Phase II Trial of Cabozantinib With Patients With Refractory GCTs — Indianapolis, Indiana
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours — New York, New York
Explore by condition: All Germ Cell Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.